[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR950702580A - Nimesulide salt cyclodextrin inclusion complex (NEW NIMESULIDE SALT CYCLODEXTRINE INCLUSION COMPLEXES) - Google Patents

Nimesulide salt cyclodextrin inclusion complex (NEW NIMESULIDE SALT CYCLODEXTRINE INCLUSION COMPLEXES) Download PDF

Info

Publication number
KR950702580A
KR950702580A KR1019950700275A KR19950700275A KR950702580A KR 950702580 A KR950702580 A KR 950702580A KR 1019950700275 A KR1019950700275 A KR 1019950700275A KR 19950700275 A KR19950700275 A KR 19950700275A KR 950702580 A KR950702580 A KR 950702580A
Authority
KR
South Korea
Prior art keywords
cyclodextrin
nimesulide
alkali
alkaline earth
inclusion complex
Prior art date
Application number
KR1019950700275A
Other languages
Korean (ko)
Inventor
제크지 요셉
Original Assignee
제크지 요셉
유로파마슈티컬스 에스.에이.
요셉 제즈틀리
사이클로랩 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제크지 요셉, 유로파마슈티컬스 에스.에이., 요셉 제즈틀리, 사이클로랩 리미티드 filed Critical 제크지 요셉
Publication of KR950702580A publication Critical patent/KR950702580A/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

PCT No. PCT/HU94/00014 Sec. 371 Date Mar. 21, 1995 Sec. 102(e) Date Mar. 21, 1995 PCT Filed May 18, 1994 PCT Pub. No. WO94/28031 PCT Pub. Date Dec. 8, 1994Inclusion complexes of nimesulide alkali and alkaline earth salts with cyclodextrins and cyclodextrin derivatives are disclosed. Compositions containing the inclusion complexes, processes for the preparation of the complexes as well as methods to use the same as pharmaceuticals are disclosed.

Description

니메술라이드 염 시클로덱스트린 봉입 복합체(NEW NIMESULIDE SALT CYCLODEXTRINE INCLUSION COMPLEXES)Nimesulide salt cyclodextrin inclusion complex (NEW NIMESULIDE SALT CYCLODEXTRINE INCLUSION COMPLEXES)

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 본 발명의 화합물의구조식이고,1 is a structural formula of a compound of the present invention,

제2도는 SLAP술라이드의 염과 상기 염/β CD 복합체의 pH에 따른 함량을 도시한 그래프이고,Figure 2 is a graph showing the pH-dependent content of the salt of the SLAP sulfide and the salt / β CD complex,

제3A도 및 B도는 각각 본 발명의 화합물의 온도에 따른 열흐름을 도시한 그래프이다.3A and B are graphs showing heat flow with temperature of the compounds of the present invention, respectively.

Claims (11)

하기 일반식(Ⅰ)의 니메술라이드 알칼리 및 알칼리 토류 염과 시클로덱스트린 및 시클로덱스트린 유도체와의 봉입 봉합체 :Encapsulation of Nimesulide Alkali and Alkaline Earth Salts of the following Formula (I) with Cyclodextrin and Cyclodextrin Derivatives: 상기 식에서, A는 알칼리 및 알칼리 토류 이온을 나타낸다.Wherein A represents alkali and alkaline earth ions. 염의 시클로덱스트린에 대한 몰 비율이 1 : 1 또는 1 : 2인 니메술라이드 나트륨, 칼륨, 마그네슘 또는 칼슘 염과 β-시클로덱스트린 또는 감마 시클로덱스트린과의 봉입 복합체.Encapsulation complex of nimesulide sodium, potassium, magnesium or calcium salt with a molar ratio of salt to cyclodextrin of 1: 1 and β-cyclodextrin or gamma cyclodextrin. 제1항에 있어서, 시클로덱스트린 및 시클로덱스트린 유도체가 α, β 및 감마시클로덱흐트린, 및/또는 시클로덱스트린의 알킬 또는 히록시알킬 유도체, 바람직하게는 메틸 β-시클로덱스트린 또는 히드록시프로필-β-시클로덱스트린인 것을 특징으로 하는 봉입 복합체.The cyclodextrin and cyclodextrin derivatives according to claim 1, wherein the cyclodextrin and cyclodextrin derivatives are α, β and gammacyclodextrin, and / or alkyl or hydroxyalkyl derivatives of cyclodextrin, preferably methyl β-cyclodextrin or hydroxypropyl-β. -An inclusion complex characterized in that it is a cyclodextrin. 제1항에 있어서, 니메술라이드 알칼리가 니메술라이드 나트륨 염인 것을 특징으로 하는 봉입 복합체.The inclusion complex of claim 1, wherein the nimesulide alkali is a nimesulide sodium salt. 니메술라이드 알칼리 및 알칼리 토류 염을 물의 존재하에 시클로덱스트린 또는 시클로덱스트린 유도체와 pH 7 내지 pH 9.5, 바람직하게는 pH 7.5 내지 8.5에서 반응시키는 것을 특징으로 하는, 니메술라이드 알칼리 및 알칼리 토류 염과 시클로덱스트리 또는 시클로덱스트린 유도체와의 봉입 복합체의 제조방법.Nimesulide alkali and alkaline earth salts and cyclos are characterized in that the reaction of the nimesulfide alkali and alkaline earth salts with a cyclodextrin or cyclodextrin derivative in the presence of water at pH 7 to pH 9.5, preferably pH 7.5 to 8.5 Process for the preparation of inclusion complexes with dextrins or cyclodextrin derivatives. 제5하에 있어서, 물중의 SLAP술라이드의 현탁액을 알칼리 및 알칼리 토류 수산화물, 알칼리 및 알칼리 토류 탄산염, -탄산 수소-, 인산염, 바람직하게는 수산화 나트륨, 인산 이나트륨 및/또는 탄산 수소 나트룸 또는 다른 완충제를 사용하여 7 내지 9.5, 바람직하게는 7.5 내지 8.5의 pH값으로 조정함으로써 반응 혼합물중에서 제자리 형성된 니메술라이드 알칼리 및 알칼리 토류 염을 사용하는 것을 특징으로 하는 방법.The method of claim 5, wherein the suspension of SLAP sulfide in water is added to alkali and alkaline earth hydroxides, alkali and alkaline earth carbonates, hydrogen carbonate, phosphate salts, preferably sodium hydroxide, disodium phosphate and / or hydrogen nitrate or other. A process comprising the use of nimesulide alkali and alkaline earth salts formed in situ in the reaction mixture by adjusting to a pH value of 7 to 9.5, preferably 7.5 to 8.5 using a buffer. 제5항 또는 6항에 있어서, 복합체 형성후에 동결-건조, 분무-건조, 저온 진공 증발, 진공 건조 또는 다른 공지의 방법에 의하여 물을 제거하는 것을 특징으로 하는 방법.7. Method according to claim 5 or 6, characterized in that the water is removed by freeze-drying, spray-drying, low temperature vacuum evaporation, vacuum drying or other known method after complex formation. 활성 성분으로서 니메술라이드 알칼리 및 알칼리 토류 염과 시클로덱스트린 또는 시클로덱스트린 유도체와의 봉입 복합체를 함유하는 것을 특징으로 하는, 니메술라이드 및 시클로덱스트린 또는 시클로덱스트린 유도체를 포함하는 고도로 가용성의 생리적으로 허용되는 봉입 복합체를 함유하는 약제학적 조성물.A highly soluble physiologically acceptable, comprising nimesulide and cyclodextrins or cyclodextrin derivatives, which are characterized as containing an inclusion complex of nimesulide alkali and alkaline earth salts with cyclodextrins or cyclodextrin derivatives as active ingredients. Pharmaceutical compositions containing inclusion complexes. 제8항에 있어서, 활성 성분으로서 니메술라이드 나트륨 염과 β-시클로덱스트린의, 가능하다면 다른 약제학적으로 허용되는 성분들과의 봉입 복합체를 함유하는 것을 특징으로 하는 약제학적 조성물.9. A pharmaceutical composition according to claim 8, which contains as its active ingredient a inclusion complex of nimesulide sodium salt with β-cyclodextrin, if possible, with other pharmaceutically acceptable ingredients. 니메술라이드 알칼리 및 알칼리 토류 염과 형성된 시클로덱스트린 또는 시클로덱스트린 유도체의 봉입 복합체의 유효량을 환자에게 투여하는 것을 특징으로 하는, 항염증 및/또는 진통 치료가 요구되는 환자의 치료 방법.A method of treating a patient in need of anti-inflammatory and / or analgesic treatment, characterized by administering to the patient an effective amount of the inclusion complex of nimesulde alkali and alkaline earth salts and the formed cyclodextrin or cyclodextrin derivative. 니메술라이드 나트륨 염과 형성된 β-시클로덱스트린의 봉입 복합체의 유료량을 환자에게 투여하는 것을 특징으로 하는, 항염증 및/또는 진통 치료가 요구되는 환자의 치료 방법.A method of treating a patient in need of anti-inflammatory and / or analgesic treatment, characterized by administering to the patient a toll of the inclusion complex of nimesulide sodium salt and β-cyclodextrin formed. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950700275A 1993-05-24 1994-05-18 Nimesulide salt cyclodextrin inclusion complex (NEW NIMESULIDE SALT CYCLODEXTRINE INCLUSION COMPLEXES) KR950702580A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU9301518A HU210922B (en) 1993-05-24 1993-05-24 Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
HUP93-01518 1993-05-24
PCT/HU1994/000014 WO1994028031A1 (en) 1993-05-24 1994-05-18 New nimesulide salt cyclodextrin inclusion complexes

Publications (1)

Publication Number Publication Date
KR950702580A true KR950702580A (en) 1995-07-29

Family

ID=10983630

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950700275A KR950702580A (en) 1993-05-24 1994-05-18 Nimesulide salt cyclodextrin inclusion complex (NEW NIMESULIDE SALT CYCLODEXTRINE INCLUSION COMPLEXES)

Country Status (17)

Country Link
US (1) US5744165A (en)
EP (1) EP0656015B1 (en)
JP (1) JPH07509498A (en)
KR (1) KR950702580A (en)
AT (1) ATE170194T1 (en)
AU (1) AU675146B2 (en)
CA (1) CA2140887C (en)
CZ (1) CZ285962B6 (en)
DE (1) DE69412760T2 (en)
DK (1) DK0656015T3 (en)
ES (1) ES2124893T3 (en)
FI (1) FI950294A0 (en)
HU (1) HU210922B (en)
NO (1) NO307570B1 (en)
RU (1) RU2129564C1 (en)
SI (1) SI0656015T1 (en)
WO (1) WO1994028031A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019318A1 (en) * 1993-02-19 1994-09-01 Taisho Pharmaceutical Co., Ltd. 5-aminoacetylaminosulfonanilide compound
HUP9601442A3 (en) * 1995-07-25 1999-03-29 Panacea Biotec Ltd Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them
UA57734C2 (en) 1996-05-07 2003-07-15 Пфайзер Інк. Arylheterocyclic inclusion complexes
IN186315B (en) * 1996-12-12 2001-08-04 Panacea Biotec Ltd
ES2129010B1 (en) * 1997-01-02 2000-01-16 Gold Oscar COMPOSITION OF PROLONGED ACTION IN GRANULES CONTAINING 4-NITRO-2- PHENOXIMETANSULFONANILIDA AND ITS PREPARATION PROCEDURE.
IT1291895B1 (en) 1997-04-24 1999-01-21 Errekappa Euroterapici S P A FLUID PHARMACEUTICAL PREPARATION BASED ON NIMESULIDE FOR ORAL AND RHINOPHARYNGAL USE
IT1298221B1 (en) * 1998-02-10 1999-12-20 Helsinn Healthcare Sa MICRONIZED SALTS OF NIMESULIDE
IT1318588B1 (en) * 2000-06-20 2003-08-27 Helsinn Healthcare Sa USE OF NIMESULIDE IN THE TREATMENT OF DERMATOLOGICAL PATHOLOGIES.
EP1172101A1 (en) * 2000-06-20 2002-01-16 Helsinn Healthcare S.A. The use of nimesulide for the treatment of psoriasis and psoriatic arthritis
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
WO2004022099A2 (en) 2002-09-06 2004-03-18 Insert Therapeutics, Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
KR20050051686A (en) 2002-10-09 2005-06-01 인설트 테라페틱스, 인코퍼레이티드 Cyclodextrin-based materials, compositions and uses related thereto
CN1511828A (en) * 2002-12-31 2004-07-14 �й������ž�����ҽѧ��ѧԺ����ҽ Sufonic aniline derivatives and their medicinal use
DE102004060914A1 (en) * 2004-12-17 2006-07-06 Bioghurt Biogarde Gmbh & Co. Kg Use of lipoic acid-containing cyclodextrin complexes
JP2010516625A (en) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド Polymer-drug conjugates with tether groups for controlled drug delivery
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN109608370A (en) * 2019-01-22 2019-04-12 山西康斯亚森生物科技有限公司 Aulin derivative and Preparation method and use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5920230A (en) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト Drug containing piruprophen
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
IT1248475B (en) * 1990-05-22 1995-01-19 Angeli Inst Spa INCLUSION COMPOUNDS OF NIMESULIDE WITH CYCLODESTRINE

Also Published As

Publication number Publication date
HU210922B (en) 1995-09-28
JPH07509498A (en) 1995-10-19
FI950294A (en) 1995-01-24
AU7081394A (en) 1994-12-20
CA2140887A1 (en) 1994-12-08
HUT68239A (en) 1995-06-28
NO950243D0 (en) 1995-01-23
SI0656015T1 (en) 1999-02-28
CA2140887C (en) 2000-08-01
CZ16395A3 (en) 1995-10-18
ES2124893T3 (en) 1999-02-16
FI950294A0 (en) 1995-01-24
HU9301518D0 (en) 1993-09-28
AU675146B2 (en) 1997-01-23
US5744165A (en) 1998-04-28
DE69412760D1 (en) 1998-10-01
NO950243L (en) 1995-03-13
RU95105977A (en) 1997-02-10
EP0656015B1 (en) 1998-08-26
NO307570B1 (en) 2000-04-25
DE69412760T2 (en) 1999-05-20
CZ285962B6 (en) 1999-12-15
RU2129564C1 (en) 1999-04-27
DK0656015T3 (en) 1999-05-25
ATE170194T1 (en) 1998-09-15
WO1994028031A1 (en) 1994-12-08
EP0656015A1 (en) 1995-06-07

Similar Documents

Publication Publication Date Title
KR950702580A (en) Nimesulide salt cyclodextrin inclusion complex (NEW NIMESULIDE SALT CYCLODEXTRINE INCLUSION COMPLEXES)
HUP9701690A2 (en) Tetrahydrofuran derivatives as antifungals and pharmaceutical compositions containing the same
KR890011823A (en) Benzoyl phenylacetic acid derivative pharmaceutical composition
ES2122217T3 (en) COSMETIC COMPOSITIONS CONTAINING NANOCAPSULES.
KR890015738A (en) Pharmaceutical composition for oral permeation based on a phosphonic acid derivative
EA199900937A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING VORIKONAZOL
ES2196527T3 (en) DERIVATIVES OF 11,15-O-DIALQUILPROSTAGLANDINA E, ITS PRODUCTION PROCEDURE AND MEDICATIONS THAT INCLUDE THESE AS THE ACTIVE PRINCIPLE.
SE7614258L (en) PROCEDURE FOR THE PREPARATION OF CHINAZOLO DERIVATIVE
KR870008580A (en) Anti tartar toothpaste
BR0014615A (en) Derived from phosphonic acid which has inhibitory activity against carboxypeptidase b
DK264388A (en) METHOD OF PREPARING CYCLOOCTAAMYLOSE
KR960704541A (en) Hydroxy ions and compounds that modulate these ions, compositions using the formulations, methods of treatment using the formulations and methods of making the same (Hydroxyl lons as Unique Therapeutic Agents and Compounds that Modulate These Ions, Compositions Employing These Agents, Therapeutic Methods for Using Such Agents and Processes for Preparing Them)
ATE163265T1 (en) ASSOLUBLE PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRONE DERIVATIVES AND CALCIUM SALTS
KR970706844A (en) A Storage Stable Water Solution for Infusion Containing A Thrombin Inhibitor
KR880001154B1 (en) The stability method of antibiotics
JP2814549B2 (en) Oral composition
BR9917315A (en) Medicinal compositions for immediate release for oral use
KR900012925A (en) Indole derivatives
RU95104235A (en) Agent for fertility control and pharmaceutical composition containing thereof
KR970704432A (en) REMEDY FOR HYPERLIPIDEMIA
JPH06107539A (en) Tyrosinase inhibitor
US4178454A (en) Stabilized prostaglandin E composition
SE8205868L (en) CERTAIN 4-PHENYL-4-OXO-2-BUTENIC ACID DERIVATIVES FOR USE AS MEDICINAL PRODUCTS AND COMPOSITIONS CONTAINING THEM
KR0135716B1 (en) Dental desensitizing composition
NO960700L (en) Isothiazolone material and method for stabilizing aqueous isothiazolone solution

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid